Classification under uncertainty: data analysis for diagnostic antibody testing.

Formulating accurate and robust classification strategies is a key challenge of developing diagnostic and antibody tests. Methods that do not explicitly account for disease prevalence and uncertainty therein can lead to significant classification errors. We present a novel method that leverages optimal decision theory to address this problem. As a preliminary step, we develop an analysis that uses an assumed prevalence and conditional probability models of diagnostic measurement outcomes to define optimal (in the sense of minimizing rates of false positives and false negatives) classification domains. Critically, we demonstrate how this strategy can be generalized to a setting in which the prevalence is unknown by either (i) defining a third class of hold-out samples that require further testing or (ii) using an adaptive algorithm to estimate prevalence prior to defining classification domains. We also provide examples for a recently published SARS-CoV-2 serology test and discuss how measurement uncertainty (e.g. associated with instrumentation) can be incorporated into the analysis. We find that our new strategy decreases classification error by up to a decade relative to more traditional methods based on confidence intervals. Moreover, it establishes a theoretical foundation for generalizing techniques such as receiver operating characteristics by connecting them to the broader field of optimization.

[1]  J. Berger Statistical Decision Theory and Bayesian Analysis , 1988 .

[2]  Jacobson Rh Validation of serological assays for diagnosis of infectious diseases. , 1998 .

[3]  Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting , 2020, The Journal of infectious diseases.

[4]  J. Montoya,et al.  Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates , 2020, Nature Biomedical Engineering.

[5]  A. Kirk,et al.  Biomarkers for kidney transplant rejection , 2014, Nature Reviews Nephrology.

[6]  M. Fay,et al.  Standardization of enzyme-linked immunosorbent assays for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling , 2020, medRxiv.

[7]  Journal de Mathématiques pures et appliquées , 1889 .

[8]  R. Caflisch Monte Carlo and quasi-Monte Carlo methods , 1998, Acta Numerica.

[9]  Manish M Patel,et al.  Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee. , 2020, JAMA.

[10]  A. Huissoon,et al.  SARS-CoV-2 serology: Test, test, test, but interpret with caution! , 2020, Clinical medicine.

[11]  C. Florkowski Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests. , 2008, The Clinical biochemist. Reviews.

[12]  D. Lowy,et al.  The COVID-19 Serology Studies Workshop: Recommendations and Challenges , 2020, Immunity.

[13]  Xinxin Zhang,et al.  Sensitivity and specificity of SARS-CoV-2 S1 subunit in COVID-19 serology assays , 2020, Cell discovery.

[14]  James O. Berger,et al.  Statistical Decision Theory and Bayesian Analysis, Second Edition , 1985 .

[15]  Paul N. Patrone,et al.  Beyond histograms: efficiently estimating radial distribution functions via spectral Monte Carlo. , 2016, The Journal of chemical physics.

[16]  Y. Yazdanpanah,et al.  A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations , 2020, Science Translational Medicine.

[17]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[18]  O. Tsang,et al.  ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection , 2020, Nature Immunology.

[19]  A. Pain,et al.  SARS-CoV-2 S1 and N-based serological assays reveal rapid seroconversion and induction of specific antibody response in COVID-19 patients , 2020, Scientific reports.

[20]  E. Iso,et al.  Measurement Uncertainty and Probability: Guide to the Expression of Uncertainty in Measurement , 1995 .

[21]  Otto O. Yang,et al.  Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19 , 2020, The New England journal of medicine.